O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Government Pricing Director

Full-Time
$186.5k - $278.9k/yr+ Incentive opportunity
Expert
Bachelor's, MBA, JD
Remote in USA
Remote
Risk & ComplianceRegulatory Compliance & Ethics

About the job

Requirements
  • A Bachelor's degree in Accounting, Finance, or Business Administration.
  • 10+ years of progressive experience in the pharmaceutical or biotech industry.
  • 5+ years of direct experience focused on statutory Government Pricing calculations, operations, and compliance.
  • A proven track record of managing technical analyst teams, handling external audits, and presenting complex regulatory risks to senior executives.
Responsibilities
  • Lead all federally mandated price calculations, including Medicaid Average Manufacturer Price and Best Price, Medicare Average Sales Price, and VA Non-FAMP pricing.
  • Manage quarterly and annual reporting certifications, analyze pricing trends and anomalies, and ensure data accuracy through validation processes with audit teams.
  • Institute Government Pricing checks for accuracy and completeness, including independent parallel calculations, model setup validation, reasonableness testing of Government Pricing changes, and assessment of business impacts.
  • Oversee processing and payment of government rebates and discounts, including Medicaid rebates, the Medicare Part D manufacturer discount program, and Inflation Reduction Act inflation rebates.
  • Manage Federal Supply Schedule contracts, Department of Defense blanket purchase agreements, and Medicaid supplemental agreement negotiations with state programs.
  • Ensure compliance with evolving federal and state requirements, including state price transparency reporting, Medicare Drug Price Negotiation under the Inflation Reduction Act, and bona fide service fee evaluations.
  • Work with internal and external legal counsel to interpret Centers for Medicare & Medicaid Services guidance and develop compliant contracting language.
  • Collaborate with Contract Operations on commercial rebate alignment, Market Access on government account strategy, Gross-to-Net forecasting teams on pricing impact analysis, and Pricing Committees on government price calculations.
  • Educate stakeholders on government pricing implications through lunch-and-learns, annual meetings, and ongoing communications.
  • Oversee third-party vendors and evaluate technology platforms for contract management, rebate analysis, and financial payments.
  • Drive data visibility initiatives through Power BI dashboards and enhanced reporting to enable proactive monitoring.
  • Manage complex dispute processes with state Medicaid agencies, particularly disputes involving 340B duplicate discounts.
  • Lead process improvement initiatives to reduce manual workload and increase the team's capacity for strategic analysis.
Desired Qualifications
  • An MBA or JD is highly preferred.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Student Loan Assistance
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.